Analysis of:
ASCRS members adopting latest refractive advances, survey finds (www.osnsupersite.com)
This survey from the 2006 survey of members of the American Society of Cataract and Refractive Surgery highlights emerging trends in refractive surgery showing large increases in wavefront, LASEK, and Phakic IOLS. There was a smaller increase in Intralase. Refractive surgery...
Analysis of:
Research yields new horizons for intraocular therapies (www.osnsupersite.com)
At the a keynote lecture at the Pan-American Association of Ophthalmology meeting, there is talk about the exciting new intraocular therapies. Much of this excitement has been generated with the use of Anti-Vegf agents (Macugen, Genetech) for retinal disease; and now those ideas are being applied...
Analysis of:
Corneal imaging devices becoming increasingly integrated, expanding functions (www.osnsupersite.com)
At a talk at the Pan-American Association of Ophthalmology meeting, new corneal images devices offer more information and features for anterior segment surgeons. These new devices would be attractive to corneal specialists, refractive surgeons, and even general ophthalmologists.
Analysis of:
Market Report -- In Play (OCCX) (news.moneycentral.msn.com)
Laser eye-treatment company TLC Vision Corp. said it agreed to sell all the common shares of OccuLogix Inc. to JEGC OCC Corp which is owned by a private equity firm. Occulogix has some emerging therapies in different areas of eye care including Age Related Macular Degeneration and Glaucoma. ...
Analysis of:
CDC warns about contact lens solution (news.yahoo.com)
This article reports a contact lens associated infection with Advanced Medical Optics contact lens solution. Despite owning less than 10% of the Market Share, AMO Complete® MoisturePlus™ (AMOCMP) multipurpose cleaning solution has been implicated in 60% of the cases of Acanthamoeba...
Analysis of:
Vegf Trap-Eye Phase 2 Wet Amd Results Reported At Arvo Annual Meeting (www.pipelinereview.com)
The VEGF Trap from Regeneron is a protein made up off human VEGF receptors fused to human immunoglobulin. This compound binds VEGF, preventing VEGF from binding to its natural receptors, interrupting the angiogenic cascade. The phase II study presented at 2007 ARVO showed promising results in patients...
Analysis of:
Ranibizumab, PDT combination successfully treats neovascular AMD (www.osnsupersite.com)
At the recent ARVO meeting, Italian researchers performing a randomized clinical trial on patients with wet AMD found that patients treated with photodynamic therapy (PDT) with Visudyne (verteporfin, Novartis) plus Lucentis(ranibizumab, Genentech) had a better visual result than patients treated with...
Analysis of:
Fish and Vitamin D Linked to Lower Risk of Macular Degeneration (www.medpagetoday.com)
This dietary case control study showed that higher dietary levels of omega-3 fatty acids, mainly from fatty fish, reduced the risk of age-related macular degeneration by 39%. This is very exciting and supports previous obersvational studies showing the protective effects of diet heavy in fish...
Analysis of:
Ranibizumab, PDT combination successfully treats neovascular AMD (www.osnsupersite.com)
This study from Italy shows that PDT combined with monthly Lucentis is much more beneficial compared to PDT alone. Does this data show a role for PDT in the current anti-Vegf era and allow Novartis to still a claim share in this market?
Analysis of:
Vegf Trap-Eye Phase 2 Wet Amd Results Reported At Arvo Annual Meeting (www.pipelinereview.com)
The treatment of "wet" Age-related macular degeneration is a billion dollar market. There has been much excitement regarding the management of of "wet" AMD centered on inhibiting vascular endothelial growth factor (VEGF). Over the past three years, there have been many inhibitors of VEGF...